These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Nakajima Y; Ito T; Maeda Y; Ichiki S; Kobayashi S; Ando N; Hussein MH; Kurono Y; Sugiyama N; Togari H Brain Dev; 2011 Nov; 33(10):816-23. PubMed ID: 21196091 [TBL] [Abstract][Full Text] [Related]
24. Blood ammonia level during valproic acid therapy. Kugoh T; Yamamoto M; Hosokawa K Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472 [TBL] [Abstract][Full Text] [Related]
25. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247 [TBL] [Abstract][Full Text] [Related]
26. Certain aspects of interaction between sodium valproate and other anticonvulsant drugs in the therapy of epilepsy in children. Sobaniec W Mater Med Pol; 1992; 24(2):115-9. PubMed ID: 1307765 [TBL] [Abstract][Full Text] [Related]
29. Serum total amylase, pancreatic amylase and lipase activities in epileptic children treated with sodium valproate monotherapy. Voudris K; Attilakos A; Katsarou E; Mastroyianni S; Dimou S; Skardoutsou A; Prassouli A; Garoufi A Brain Dev; 2006 Oct; 28(9):572-5. PubMed ID: 16730152 [TBL] [Abstract][Full Text] [Related]
30. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. Luef G; Abraham I; Haslinger M; Trinka E; Seppi K; Unterberger I; Alge A; Windisch J; Lechleitner M; Bauer G J Neurol; 2002 Jul; 249(7):835-41. PubMed ID: 12140666 [TBL] [Abstract][Full Text] [Related]
31. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Voudris KA; Attilakos A; Katsarou E; Drakatos A; Dimou S; Mastroyianni S; Skardoutsou A; Prassouli A; Garoufi A Epilepsy Res; 2006 Aug; 70(2-3):211-7. PubMed ID: 16781120 [TBL] [Abstract][Full Text] [Related]
32. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Ugras M; Yakinci C Brain Dev; 2006 Oct; 28(9):549-53. PubMed ID: 16842952 [TBL] [Abstract][Full Text] [Related]
33. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study. Attilakos A; Voudris KA; Garoufi A; Mastroyianni S; Dimou S; Prassouli A; Katsarou E Eur J Paediatr Neurol; 2006; 10(5-6):237-40. PubMed ID: 17035050 [TBL] [Abstract][Full Text] [Related]
34. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579 [TBL] [Abstract][Full Text] [Related]
35. Alterations in the carnitine metabolism in epileptic children treated with valproic acid. Chung S; Choi J; Hyun T; Rha Y; Bae C J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096 [TBL] [Abstract][Full Text] [Related]
36. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Nadebaum C; Anderson V; Vajda F; Reutens D; Barton S; Wood A J Int Neuropsychol Soc; 2011 Jan; 17(1):133-42. PubMed ID: 21092354 [TBL] [Abstract][Full Text] [Related]
37. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure. Panda S; Radhakrishnan K J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456 [TBL] [Abstract][Full Text] [Related]
38. Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. Grosso S; Luisi S; Mostardini R; Matera M; Barlocco EG; Casarosa E; Balestri P; Petraglia F Neuroendocrinology; 2011; 93(3):159-64. PubMed ID: 20980729 [TBL] [Abstract][Full Text] [Related]
39. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182 [TBL] [Abstract][Full Text] [Related]